PortalPublikationenSystemic treatment of liver metastases from colorectal cance...

Systemic treatment of liver metastases from colorectal cancer

Standard

Systemic treatment of liver metastases from colorectal cancer. / Stein, Alexander; Schmoll, Hans-Joachim.

in: THER ADV MED ONCOL, Jahrgang 5, Nr. 3, 01.05.2013, S. 193-203.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Transfer › Begutachtung

Harvard

Stein, A & Schmoll, H-J 2013, 'Systemic treatment of liver metastases from colorectal cancer', THER ADV MED ONCOL, Jg. 5, Nr. 3, S. 193-203. https://doi.org/10.1177/1758834012473347

APA

Stein, A., & Schmoll, H-J. (2013). Systemic treatment of liver metastases from colorectal cancer. THER ADV MED ONCOL, 5(3), 193-203. https://doi.org/10.1177/1758834012473347

Vancouver

Stein A, Schmoll H-J. Systemic treatment of liver metastases from colorectal cancer. THER ADV MED ONCOL. 2013 Mai 1;5(3):193-203. https://doi.org/10.1177/1758834012473347

Bibtex

@article{d19532e9a5bc4a39bc273dda54cb76fd,
title = "Systemic treatment of liver metastases from colorectal cancer",
abstract = "Patients presenting with synchronous or metachronous colorectal cancer liver metastases (CLM) should be evaluated for multimodal management with curative intent. Preoperative systemic chemotherapy shows beneficial impact on adjuvant progression-free survival and also borderline on overall survival, without significantly increasing initially R0 resectable patients postoperative complication rates. Postoperative chemotherapy recommended based on the perioperative trial experience for those patients achieving at least stable disease during preoperative chemotherapy, or based on the adjuvant trials for patients receiving upfront resection. 'Borderline' resectable CLM, preoperative chemotherapy plays an important role in both in achievement of a resectable status and improvement of prognosis. Recent 4 drug combinations demonstrated response rates up to 80% even for advanced disease and are thus promising regimens for further evaluation in patients with resectable or unresectable liver-limited (+/- lung) disease.",
author = "Alexander Stein and Hans-Joachim Schmoll",
year = "2013",
month = may,
day = "1",
doi = "10.1177/1758834012473347",
language = "English",
volume = "5",
pages = "193--203",
journal = "THER ADV MED ONCOL",
issn = "1758-8340",
publisher = "Old City Publishing",
number = "3",

}

RIS

TY - JOUR

T1 - Systemic treatment of liver metastases from colorectal cancer

AU - Stein, Alexander

AU - Schmoll, Hans-Joachim

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Patients presenting with synchronous or metachronous colorectal cancer liver metastases (CLM) should be evaluated for multimodal management with curative intent. Preoperative systemic chemotherapy shows beneficial impact on adjuvant progression-free survival and also borderline on overall survival, without significantly increasing initially R0 resectable patients postoperative complication rates. Postoperative chemotherapy recommended based on the perioperative trial experience for those patients achieving at least stable disease during preoperative chemotherapy, or based on the adjuvant trials for patients receiving upfront resection. 'Borderline' resectable CLM, preoperative chemotherapy plays an important role in both in achievement of a resectable status and improvement of prognosis. Recent 4 drug combinations demonstrated response rates up to 80% even for advanced disease and are thus promising regimens for further evaluation in patients with resectable or unresectable liver-limited (+/- lung) disease.

AB - Patients presenting with synchronous or metachronous colorectal cancer liver metastases (CLM) should be evaluated for multimodal management with curative intent. Preoperative systemic chemotherapy shows beneficial impact on adjuvant progression-free survival and also borderline on overall survival, without significantly increasing initially R0 resectable patients postoperative complication rates. Postoperative chemotherapy recommended based on the perioperative trial experience for those patients achieving at least stable disease during preoperative chemotherapy, or based on the adjuvant trials for patients receiving upfront resection. 'Borderline' resectable CLM, preoperative chemotherapy plays an important role in both in achievement of a resectable status and improvement of prognosis. Recent 4 drug combinations demonstrated response rates up to 80% even for advanced disease and are thus promising regimens for further evaluation in patients with resectable or unresectable liver-limited (+/- lung) disease.

U2 - 10.1177/1758834012473347

DO - 10.1177/1758834012473347

M3 - SCORING: Journal article

C2 - 23634197

VL - 5

SP - 193

EP - 203

JO - THER ADV MED ONCOL

JF - THER ADV MED ONCOL

SN - 1758-8340

IS - 3

ER -